GlassScriptPhysician profile
Janice Hennon
NPI 1295243202
$7,336.42
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,960 · 2022: $317 · 2023: $3,920 · 2024: $1,140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,637 · Food and Beverage: $2,424.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,636.54 |
| Food and Beverage | $2,423.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Bioscience INC. | $3,301.34 | 2023 | |
| Novo Nordisk INC | $1,051.35 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $425.02 | 2024 | Iqirvo, Bylvay |
| Gilead Sciences, INC. | $346.77 | 2023-2024 | Epclusa |
| Intercept Pharmaceuticals, INC. | $274.73 | 2023-2024 | Ocaliva |
| Redhill Biopharma INC. | $219.79 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $199.34 | 2023-2024 | Imfinzi |
| Abbott Laboratories | $190.91 | 2021-2024 | Freestyle Libre 2 |
| Madrigal Pharmaceuticals | $178.70 | 2024 | Rezdiffra, Resmetirom |
| Currax Pharmaceuticals LLC | $170.08 | 2021-2022 | |
| Si-Bone, INC. | $147.06 | 2021 | |
| Boston Scientific Corporation | $140.78 | 2023 | Therasphere Y90 Glass Microspheres 10 Gbq |
| Lucid Diagnostics INC. | $127.14 | 2022 | |
| Inari Medical, INC. | $125.00 | 2022 | |
| Lilly USA, LLC | $63.74 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $61.64 | 2021 | |
| Acella Pharmaceuticals, LLC | $56.35 | 2023 | NP Thyroid 60 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $51.76 | 2023-2024 | Xifaxan |
| Vivus LLC | $47.73 | 2021 | |
| Daiichi Sankyo INC. | $38.46 | 2021 | |
| Mirum Pharmaceuticals, INC. | $32.92 | 2024 | Livmarli |
| Orphalan INC | $30.91 | 2024 | Cuvrior |
| Amarin Pharma, INC. | $19.29 | 2021 | |
| Rhythm Pharmaceuticals, INC. | $18.67 | 2022 | |
| Mallinckrodt Hospital Products INC. | $16.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janice Hennon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.